Cargando…

Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India

BACKGROUND: Miltefosine unresponsive and relapse cases of visceral leishmaniasis (VL) are increasingly being reported. However, there has been no laboratory confirmed reports of miltefosine resistance in VL. Here, we report two laboratory confirmed cases of VL from India. METHODS: Two patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Srivastava, Saumya, Mishra, Jyotsna, Gupta, Anil Kumar, Singh, Amit, Shankar, Prem, Singh, Sarman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5282768/
https://www.ncbi.nlm.nih.gov/pubmed/28137296
http://dx.doi.org/10.1186/s13071-017-1969-z
_version_ 1782503388831809536
author Srivastava, Saumya
Mishra, Jyotsna
Gupta, Anil Kumar
Singh, Amit
Shankar, Prem
Singh, Sarman
author_facet Srivastava, Saumya
Mishra, Jyotsna
Gupta, Anil Kumar
Singh, Amit
Shankar, Prem
Singh, Sarman
author_sort Srivastava, Saumya
collection PubMed
description BACKGROUND: Miltefosine unresponsive and relapse cases of visceral leishmaniasis (VL) are increasingly being reported. However, there has been no laboratory confirmed reports of miltefosine resistance in VL. Here, we report two laboratory confirmed cases of VL from India. METHODS: Two patients with VL were referred to us with suspected VL. The first patient was a native of the VL endemic state of Bihar, but residing in Delhi, a VL non-endemic area. He was treated with broad-spectrum antibiotics and antipyretics but was unresponsive to treatment. The second patient was from Jharkhand state in eastern India (adjoining Bihar), another endemic state for VL. He was refractory to anti-leishmanial treatment, which included administration of miltefosine. Following investigation, both patients were serologically positive for VL, and blood buffy coat from both patients grew Leishmania donovani. The isolates derived from both cases were characterized for their drug susceptibility, genetically characterised, and SNPs typed for LdMT and LdROS gene expression. Both patients were successfully treated with amphotericin B. RESULTS: The in vitro drug susceptibility assays carried out on both isolates showed good IC(50) values to amphotericin B (0.1 ± 0.0004 μg/ml and 0.07 ± 0.0019 μg/ml). One isolate was refractory to Sb(III) with an IC(50) of > 200 μM while the second isolate was sensitive to Sb(III) with an IC(50) of 36.70 ± 3.2 μM. However, in both the isolates, IC(50) against miltefosine was more than 10-fold higher (> 100 μM) than the standard strain DD8 (6.8 ± 0.1181 μM). Furthermore, genetic analyses demonstrated single nucleotide polymorphisms (SNPs) ((354)Tyr↔Phe and (1078)Phe↔Tyr) in the LdMT gene of the parasites. CONCLUSIONS: Here, we document two laboratory confirmed cases of miltefosine resistant VL from India. Our finding highlights the urgent need to establish control measures to prevent the spread of these strains. We also propose that LdMT gene mutation analysis could be used as a molecular marker of miltefosine resistance in L. donovani. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13071-017-1969-z) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5282768
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-52827682017-02-03 Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India Srivastava, Saumya Mishra, Jyotsna Gupta, Anil Kumar Singh, Amit Shankar, Prem Singh, Sarman Parasit Vectors Research BACKGROUND: Miltefosine unresponsive and relapse cases of visceral leishmaniasis (VL) are increasingly being reported. However, there has been no laboratory confirmed reports of miltefosine resistance in VL. Here, we report two laboratory confirmed cases of VL from India. METHODS: Two patients with VL were referred to us with suspected VL. The first patient was a native of the VL endemic state of Bihar, but residing in Delhi, a VL non-endemic area. He was treated with broad-spectrum antibiotics and antipyretics but was unresponsive to treatment. The second patient was from Jharkhand state in eastern India (adjoining Bihar), another endemic state for VL. He was refractory to anti-leishmanial treatment, which included administration of miltefosine. Following investigation, both patients were serologically positive for VL, and blood buffy coat from both patients grew Leishmania donovani. The isolates derived from both cases were characterized for their drug susceptibility, genetically characterised, and SNPs typed for LdMT and LdROS gene expression. Both patients were successfully treated with amphotericin B. RESULTS: The in vitro drug susceptibility assays carried out on both isolates showed good IC(50) values to amphotericin B (0.1 ± 0.0004 μg/ml and 0.07 ± 0.0019 μg/ml). One isolate was refractory to Sb(III) with an IC(50) of > 200 μM while the second isolate was sensitive to Sb(III) with an IC(50) of 36.70 ± 3.2 μM. However, in both the isolates, IC(50) against miltefosine was more than 10-fold higher (> 100 μM) than the standard strain DD8 (6.8 ± 0.1181 μM). Furthermore, genetic analyses demonstrated single nucleotide polymorphisms (SNPs) ((354)Tyr↔Phe and (1078)Phe↔Tyr) in the LdMT gene of the parasites. CONCLUSIONS: Here, we document two laboratory confirmed cases of miltefosine resistant VL from India. Our finding highlights the urgent need to establish control measures to prevent the spread of these strains. We also propose that LdMT gene mutation analysis could be used as a molecular marker of miltefosine resistance in L. donovani. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13071-017-1969-z) contains supplementary material, which is available to authorized users. BioMed Central 2017-01-31 /pmc/articles/PMC5282768/ /pubmed/28137296 http://dx.doi.org/10.1186/s13071-017-1969-z Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Srivastava, Saumya
Mishra, Jyotsna
Gupta, Anil Kumar
Singh, Amit
Shankar, Prem
Singh, Sarman
Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India
title Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India
title_full Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India
title_fullStr Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India
title_full_unstemmed Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India
title_short Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India
title_sort laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from india
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5282768/
https://www.ncbi.nlm.nih.gov/pubmed/28137296
http://dx.doi.org/10.1186/s13071-017-1969-z
work_keys_str_mv AT srivastavasaumya laboratoryconfirmedmiltefosineresistantcasesofvisceralleishmaniasisfromindia
AT mishrajyotsna laboratoryconfirmedmiltefosineresistantcasesofvisceralleishmaniasisfromindia
AT guptaanilkumar laboratoryconfirmedmiltefosineresistantcasesofvisceralleishmaniasisfromindia
AT singhamit laboratoryconfirmedmiltefosineresistantcasesofvisceralleishmaniasisfromindia
AT shankarprem laboratoryconfirmedmiltefosineresistantcasesofvisceralleishmaniasisfromindia
AT singhsarman laboratoryconfirmedmiltefosineresistantcasesofvisceralleishmaniasisfromindia